Management of Refractory Ascites in Cirrhosis
Serial large-volume paracentesis (LVP) with albumin replacement (6-8 g per liter of ascites removed) is the primary treatment for refractory ascites, and transjugular intrahepatic portosystemic shunt (TIPS) should be strongly considered in appropriate candidates to improve survival and quality of life. 1, 2, 3
Understanding Refractory Ascites
Refractory ascites occurs when fluid cannot be mobilized despite maximum diuretic therapy (spironolactone 400 mg/day plus furosemide 160 mg/day) for at least one week combined with salt restriction (<5 g/day), or when ascites rapidly recurs after paracentesis. This includes two subtypes: diuretic-resistant (inadequate response with <800 g weight loss over 4 days and urinary sodium less than intake) and **diuretic-intractable** (complications preventing effective diuretic dosing, such as hepatic encephalopathy, renal impairment with creatinine increase >0.3 mg/dL in 48 hours, hyponatremia <125 mmol/L, or potassium abnormalities). 1, 3
The development of refractory ascites carries a grave prognosis with median survival of approximately 6 months, making this an urgent indication for liver transplantation evaluation. 3, 4
Primary Management Strategy
Large-Volume Paracentesis with Albumin
Serial LVP remains the cornerstone of management. When performing paracentesis:
- Always administer 6-8 g of albumin per liter of ascites removed to prevent post-paracentesis circulatory dysfunction, which reduces mortality and complications including hyponatremia, acute kidney injury, and hepatic encephalopathy 1, 2
- This applies definitively to paracentesis >5 L; for <5 L, albumin should still be considered in patients with acute-on-chronic liver failure or high AKI risk 2
- LVP shortens hospital stays and is faster than diuretic therapy alone 1
Important caveat: While LVP effectively removes fluid, it does not address the underlying sodium retention. Repeated procedures increase infection and malnutrition risk from protein loss. 1
Diuretic Management in Refractory Ascites
Once refractoriness is confirmed, discontinue diuretics. The exception: if urinary sodium excretion on diuretics exceeds 30 mmol/day, maintenance therapy can be cautiously continued if tolerated. 1, 3 This prevents unnecessary electrolyte complications and renal impairment in patients who cannot respond adequately.
Continue salt restriction (<5 g/day) to reduce paracentesis frequency. 1
TIPS: The Definitive Second-Line Option
TIPS should be strongly considered for all patients with refractory ascites who meet eligibility criteria, as it provides superior ascites control and may improve survival compared to repeated paracentesis. 2, 3, 5
Patient Selection for TIPS
Exercise caution or avoid TIPS in patients with:
- Age >70 years
- Serum bilirubin >50 μmol/L (approximately 3 mg/dL)
- Platelet count <75×10⁹/L
- MELD score ≥18
- Current hepatic encephalopathy
- Active infection
- Hepatorenal syndrome 2
Key consideration: Recent evidence shows 1-year mortality after TIPS has improved to 26% in newer studies (versus 44% historically), likely reflecting better patient selection. 5 Cardiac evaluation is essential pre-TIPS to avoid cardiac decompensation. Under-dilating the TIPS at insertion and using rifaximin starting pre-procedure may reduce post-TIPS hepatic encephalopathy. 6
Alternative and Emerging Options
Alfapump System
For patients unsuitable for TIPS, the automated low-flow ascites (ALFA) pump can improve quality of life by continuously draining ascites to the bladder. However, 6-month mortality is 24% and acute kidney injury occurs in 31% of patients. 5 This is primarily a palliative option.
Long-Term Abdominal Drains (LTAD)
LTADs represent a reasonable palliative option for patients not candidates for TIPS or transplant, with recent data showing 47% reduction in hospital admissions and 55% reduction in length of stay. 7 However, spontaneous bacterial peritonitis occurs in 18% and catheter infections in 11%. 7 This should be considered case-by-case in palliative settings. 8
Long-Term Albumin Therapy
Some evidence suggests regular albumin infusions (25 g/week for one year, then biweekly) may delay refractoriness and improve survival when started early, though this remains controversial and is not universally recommended. 1, 9
Critical Management Pitfalls
Avoid these common errors:
- NSAIDs and prostaglandin inhibitors convert diuretic-sensitive patients to refractory and should be strictly avoided 10
- ACE inhibitors, angiotensin II antagonists, and α1-blockers increase renal impairment risk 3
- Aminoglycosides should be reserved only for severe infections without alternatives 3
- Continuing diuretics after refractoriness is established risks life-threatening complications without benefit
Immediate Transplant Evaluation
All patients with refractory ascites require urgent liver transplantation evaluation if not already listed. 1, 3 This is the only curative treatment, and the 6-month median survival means delays can be fatal. Prognostic scores may underestimate mortality risk in this population. 3
Palliative Care Integration
Despite 6-12 month median survival, only 33% of patients receive palliative care referral. 4 Concurrent palliative care should be initiated at refractory ascites diagnosis to optimize quality of life, facilitate advance care planning, and provide symptom management, particularly for the majority who will not receive transplantation (77-97% in most series). 4